 
[STUDY_ID_REMOVED] 
 
Study ID:  191622-112 
 
Title: BOTOX® Treatment in Pediatric Lower Limb Spasticity: Open-label Study 
 
Protocol Amendment 3 Date: 28 January 2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 1  
 Title Page 
ALLERGAN – CONFIDENTIAL 
The following contains confidential, proprietary information  
which is the property of Allergan 
STUDY TITLE 
BOTOX® Treatment in Pediatric Lower Limb  Spasticity:  Open-label Study  
 
Protocol Number:   191622-[ADDRESS_947424] Number: 2012-000084-24 
Phase: [ADDRESS_947425]: BOTOX® (botulinum toxin type A) purified 
neurotoxin complex (US Adopted Name [CONTACT_687987]) 
Sponsor: 
 Allergan (North 
America) [ADDRESS_947426] Irvine, [LOCATION_004] [LOCATION_003]92612 +[PHONE_10421] +[PHONE_10422] Allergan Ltd. 1st Floor, Marlow International, The Parkway, Marlow Buckinghamshire SL7 1YL [LOCATION_008] Tel: +44 (0) 1628 494444 Fax: +44 (0) 1628 494449  
Emergency Telephone Number(s): Refer to the Study Contacts Page. 
  
   
 
  
  
  
 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 2  
    
 
 
 
 
The following information can 
be found on FDA Form 1572 and/or study contacts page:  
Name [CONTACT_3669] [CONTACT_687966]; name, address, and statement of quali fications of each invest igator; name [CONTACT_687985]; name [CONTACT_287472]; name [CONTACT_160489]; 21 CFR 312.23 
section 6(iii)b.  

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 3  
 INVESTIGATOR SIGNATURE [CONTACT_249625]:  
STUDY LOCATION:  
 
I agree to: 
• Implement and conduct this study diligently a nd in strict compliance with the protocol, 
good clinical practices and all ap plicable laws and regulations. 
• Maintain all information supplied by [CONTACT_249595], when this information 
is submitted to an Institutional Review Board (IRB), Independent Ethics Committee 
(IEC) or another group, it will be submitted with a designation that the material is 
confidential. 
I have read this protocol in its en tirety and I agree to all aspects. 
     
Investigator Printed Name  [CONTACT_687986] :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 [ADDRESS_947427] of Figures ............................................................................................................... ............ 8  
Protocol Summary .................................................................................................................... 9  
1. Background and Clinical Rationale ................................................................................. 20  
1.1 Pediatric Spasticity ................................................................................................. 20  
1.2 Management of Spasticity in Children ................................................................... 21  
1.3 BOTOX for Management of Pediatric Spasticity .................................................. 22  
1.3.1 Use of BOTOX in Pediatric Lower Limb Spasticity ............................ 22  
1.4 Dose Justification ................................................................................................... 23  
2. Study Objectives and Clinical Hypotheses ...................................................................... 24  
2.1 Study Objectives .................................................................................................... 24  
2.2 Clinical Hypothesis ................................................................................................ 25  
3. Study Design .................................................................................................................. .. 25 
3.1 Safety Data Review Committee ............................................................................. 28  
4. Study Population and Entry Criteria ................................................................................ 28  
4.1 Number of Patients ................................................................................................. 28  
4.2 Study Population Characteristics ........................................................................... 28  
4.3 Inclusion Criteria .................................................................................................... 29  
4.4 Exclusion Criteria................................................................................................... 30  
4.5 Permissible and Prohibited Medications/Treatments ............................................. 34  
4.5.1 Permissible Medicati ons/Treatments..................................................... 34  
4.5.2 Prohibited Medications/Treatments....................................................... 36  
4.5.3 Special Diet or Activities ....................................................................... 37  
5. Study Treatments ............................................................................................................. 37 
5.1 Study Treatments and Formulations ...................................................................... 37  
5.2 Methods for Blinding ............................................................................................. 37  
5.3 Method for Assignment to  Treatment Groups ........................................................ 37  
5.4 Treatment Regimen and Dosing ............................................................................. 38  
5.4.1 Treatment Cycle 1 for De Novo Patients ............................................... 38  
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 5  
 5.4.2 Treatment Cycle 1 for Rollover Patients ............................................... 38  
5.4.3 Treatment Cycles 2 Through 5 fo r All Patients (Rollover and De Novo)
 ............................................................................................................... 38  
5.4.4 Treatment Regimen/Dosage Adjustment ............................................... 41  
5.4.5 Retreatment Visits ................................................................................. 41  
5.5 Storage of Study Medications/Treatments ............................................................. 42  
5.6 Preparation of Study Medi cations/Treatments ....................................................... 42  
5.7 Treatment Administration ...................................................................................... 42  
6. Response Measures and Summary of  Data Collection Methods ..................................... 43  
6.1 Efficacy Measures .................................................................................................. 43  
6.1.1 Primary Efficacy Measure ..................................................................... 43  
6.1.2 Safety Measures .................................................................................... 43  
6.2 Examination Procedures, Tests, Equipment, and Techniques ................................ 43  
6.3 Other Study Supplies ............................................................................................. 44  
6.4 Summary of Methods of Data Collection .............................................................. 44  
7. Statistical Procedures ....................................................................................................... 45 
7.1 Analysis Populations .............................................................................................. 45  
7.2 Collection and Derivation of Primary and Secondary Efficacy Assessments ........ 45  
7.2.1 Efficacy Variables .................................................................................. 46  
7.2.2 Primary Efficacy Variable(s) ................................................................. 46  
7.3 Hypothesis and Methods of Analysis ..................................................................... 46  
7.3.1 Efficacy Analyses .................................................................................. 46  
7.3.2 Safety Analyses ..................................................................................... 47  
7.4 Subgroup Analyses ................................................................................................. 48  
7.5 Sample Size Calculation ........................................................................................ 48  
7.6 Interim Analyses..................................................................................................... 48  
   
   
   
   
   
   
   
   

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 6  
    
   
   
   
   
8.4 Instructions for the Patients .................................................................................... 58  
8.5 Unscheduled Visits ................................................................................................. 58  
8.6 Compliance with Protocol ...................................................................................... 58  
8.7 Early Discontinuation of Patients .......................................................................... 58  
8.8 Withdrawal Criteria ................................................................................................ 59  
8.9 Study Termination .................................................................................................. 59  
9. Adverse Events ................................................................................................................  59 
9.1 Definitions .............................................................................................................. 59  
9.1.1 Adverse Event ....................................................................................... 59  
9.1.2 Serious Adverse Event .......................................................................... 60  
9.1.3 Severity .................................................................................................. 60  
9.1.4 Relationship to Study Drug or Study Procedure ................................... 61  
9.2 Procedures for Reporting Adverse Events ............................................................. 61  
9.3 Procedures for Reporting a Serious Adverse Event ............................................... 61  
10. Administrative Items ....................................................................................................... 62  
10.1 Protection of Human Subjects ................................................................................ 62  
10.1.1 Compliance with Informed Consent Regulations (US 21 CFR Part 50) 
and Relevant Country Regulations ........................................................ 62  
10.1.2 Compliance With IRB or IEC Regulations ........................................... 62  
10.1.3 Compliance With Good Clinical Practice ............................................. 63  
10.1.4 Compliance With Electronic Records;  Electronic Signatures Regulations 
(US 21 CFR Part 11) ............................................................................. 63  
10.2 Changes to the Protocol ......................................................................................... 63  
10.3 Patient Confidentiality ........................................................................................... 63  
10.3.1 Patient Privacy ....................................................................................... 63  
10.4 Documentation ....................................................................................................... 64  
10.4.1 Source Documents ................................................................................. 64  
10.4.2 Case Report Form Completion .............................................................. 65  
10.4.3 Study Summary ..................................................................................... 65  
10.4.4 Retention of Documentation ................................................................. 65  

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 7  
 10.5 Labeling, Packaging, and Return or Dis posal of Study Medications/Treatments . 66  
10.5.1 Labeling/Packaging ............................................................................... 66  
10.5.2 Clinical Supply Inventory ..................................................................... 66  
10.5.3 Return or Disposal of Study Medica tions/Treatments and/or Supplies 66  
10.6 Monitoring by [CONTACT_1034] .................................................................................... 66  
10.7 Handling of Biological Specimens......................................................................... 67  
10.8 Publications ............................................................................................................ 67  
10.9 Coordinating Investigator ...................................................................................... 67  
11. References .................................................................................................................... .... 67 
12. Attachments ................................................................................................................... .. 71 
 
   
   
   
   
   
   
   
   
   
 
   
   
   
 
 
   
   
   
12.2 Package Insert/Summary of Product Characteristics ............................................. 82  
12.3 Glossary of Abbreviations ...................................................................................... 83  
12.4 Protocol Amendment 1 Summary .......................................................................... 85  
12.5 Protocol Amendment 2 Summary .......................................................................... 87  
12.6 Protocol Amendment 3 Summary .......................................................................... 93  
 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 8  
  

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 9  
 Protocol Summary 
 
Study Compound:  BOTOX® (botulinum toxin type A) purified neurotoxin complex (US Adopted Name, 
onabotulinumtoxinA)   
Phase:  3 
Study Objectives:  To evaluate the long-term safety of repeated doses of BOTOX for the treatment of pediatric 
lower limb spasticity 
Clinical Hypothesis:  Repeated doses of BOTOX (up to 8 U/kg in the lower limb alone, up to 10 U/kg in a 
combination of both lower limbs, or up to 10 U/kg in a combination of upper and lower limbs) have an 
acceptable safety profile for treating pediatric lower limb spasticity (with or without treatm ent in the upper 
limb)   
Study Design 
Structure:  Multicenter, open–label study  
Duration:  Approximately 60 weeks 
Study Treatment Groups :  BOTOX 
Controls:  None 
Dosage/Dose Regimen (BOTOX doses are expressed per body weight) :   
There will be up to [ADDRESS_947428] treatment cycle, de novo patients (who did not participate in Allergan Study 191622-111) 
are to receive a total of 8 U/kg (not to exceed 300 U) either in a single affected lower limb or divided 
between both study limbs (referred to as the study lower limb or study lower limbs). Rollover patients (who participated in Allergan Study 191622-111) during the first treatment cycle 
may receive up to a maximum of 8 U/kg (not to exceed  300 U) in the same lower limb that was treated 
in Study 191622-111 (referred to as the study lowe r limb).  Patients with clinically significant upper 
limb spasticity may be eligible to receive BOTOX treatment in an  affected upper limb up to a 
maximum of 8 U/kg (not to exceed 300 U).  Th e combined lower and upper limb dose should not 
exceed 8 U/kg or [ADDRESS_947429] cycle. 
For treatment cycles 2 through 5, the maximum dose for a single lower limb or a single upper limb remains the same as for treatment cycle 1; the ma ximum dose for combined upper and lower limbs or 
for both lower limbs only for diplegic patients can be increased to 10 U/kg (not to exceed 340 U).  
If a patient meets the retreatment criteria, including no indication of an unacceptable safety risk, and it 
is considered clinically appropriate by [CONTACT_093], the patient should receive at least 4 U/kg in the 
study lower limb(s) every 12 to 14 weeks, with the total dose not to exceed the maximum specified for 
each treatment cycle.  
Randomization/Stratification :   
No randomization or stratification will be  performed for this open-label study. 
 
 
 
 
. 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 10  
 Study Population Characteristics 
Patients who successfully completed Study 191622- 111 without major protocol deviations (eg, 
noncompliance to protocol required procedures) and have not experienced an adverse event that, in the 
investigator’s opi[INVESTIGATOR_1649], may indi cate an unacceptable safety risk for additional BOTOX treatments may 
be eligible for enrollment in this study (referred to as rollover patients).  Patients who became pregnant 
during Study 191622-111 cannot be enrolled in this study.  
Additionally, de novo patients (who did not participate in Study 191622-111) who meet inclusion 
criteria and do not meet the exclusion criteria may be enrolled in this study. 
Number of Patients :   
Approximately 350 patients will be enrolled.  
Condition/Disease :   
Medically stable monoplegic, hemiplegic, or diplegic pediatric patients with cerebral palsy who have 
dynamic muscle contracture of the ankle plantar flexors associated with equinus foot position 
Key Inclusion Criteria :   
Rollover patients :  
• Eligible patients who successfully completed Allergan Study 191622-111 without major protocol 
deviations (eg, noncompliance to protocol-requi red procedures) and who, in the investigator’s 
clinical judgment, did not experience an adverse event that may indicate an unacceptable safety 
risk for additional BOTOX treatments 
• Stable medical condition in the investigator’s opi[INVESTIGATOR_1649] 
• Written informed consent has been obtained from parent/legally authorized representative 
• Written minor assent has been obtained in accordance with local laws and institutional review 
board (IRB)/independent ethics committee (IEC) requirements 
• Written documentation has been obtained in acco rdance with the relevant co untry and local 
privacy requirements, where appli cable (eg, Written Authorization for Use and Release of Health 
and Research Study Information for [LOCATION_002]  [US] sites and written Data Protection consent 
for European Union [EU] sites) 
• Negative urine pregnancy test at day 1 visit (for females of childbearing potential, defined as females post menarche) 
De novo patients:
 
  
• Minimum weight of 10 kg at the screening and day 1 visits 
• Monoplegic, hemiplegic, or diplegic patients with cerebral palsy with dynamic muscle contracture (spasticity confirmed by [CONTACT_697967] [HAT]) of the ankle plantar flexors.  
Equinovarus and equinovalgus deformities are acceptable. 
  
  
 
 
 
 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 11  
   
 
  
  
 
 
 
  
Key Exclusion Criteria (all patients except w h
ere noted otherwise) :  
  
• Any medical condition that may put the patient at increased risk with exposure to Botulinum 
Toxin Type A Purified Neurotoxin Complex, including diagnosed muscular dystrophy (eg, 
Duchenne’s muscular dystrophy), myasthenia gravis, Eaton-Lambert syndrome, amyotrophic 
lateral sclerosis, mitochondrial disease, or any ot her significant disease that might interfere with 
neuromuscular function 
  
 
  
  
• Uncontrolled epi[INVESTIGATOR_697963] 1 generalized seizure in any month within the 3 months prior to the day 1 visit or history of any of the following within 9 months prior to the day 
1 visit:  prolonged seizures or repetitive seizur e activity requiring administration of a rescue 
benzodiazepi[INVESTIGATOR_050] (oral, rectal, etc) more than once a month, seizures lasting more than 10 minutes, 
status epi[INVESTIGATOR_7397], or epi[INVESTIGATOR_697964]  
  
 
 
  
  
 
 
 
 
• Botulinum toxin therapy of any serotype for any condition within 3 months prior to the day 1 visit 
(de novo patients only) 
   
 
 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 12  
   
 
• History of surgical intervention of the lower leg (the knee and below of the study limb[s]) within 
12 months prior to the day 1 visit (de novo patients only) or planned surgical intervention of any 
limb(s) during the study 
   
  
  
 
Response Measures 
Safety measures:   
• Adverse events 
  
  
  
  
   
  
  
 
  
  
  
  
  
  
  
 
General Statistical Methods and Types of Analyses:    
Safety data will be analyzed  on the basis of all treated  patients based on treatment  received, defined as the 
safety population.  
  
Safety variables such as the incidence of adverse even ts, 
 
 
 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 13  
  
 
 
 
 
 
Sample Size Calculation:  
Approximately 350 patients will be enrolled.  The sample size was determined empi[INVESTIGATOR_3675]. 
 

 
 
 
Approval  Date:  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 14  
  

 
 
 
Approval  Date:  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 15  
  

 
 
 
 
Approval  Date:  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 16  
  

 
 
 
 
Approval  Date:  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 17  
  

 
 
 
Approval  Date:  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 18  
  

 
 
 
 
Approval  Date:  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 19  
  

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 20  
 1. Background and Clinical Rationale 
1.1 Pediatric Spasticity 
Spasticity is classically defined as a disorder of the sensorimotor system characterized by a 
velocity-dependent increase in muscle tone  with exaggerated tendon jerks, resulting from 
hyperexcitability of th e stretch reflex (Lance, 1980 ).  The most common cause of focal 
spasticity in children is cerebral palsy.  Cerebral palsy is a disorder caused by a 
non-progressive insult of the central  nervous system (CNS) that occurs prenatally, perinatally, 
or during the first 2 years of life and can result in functional motor impairment, irregular 
movement, and abnormal posture.  The increase in the muscle-stretch reflex causes muscle 
contraction of abnormal strength and duration.   Spastic muscles show “velocity-dependent” 
resistance to passive movement and exaggerated tendon jerks (Lance, 1980). 
The patterns of spasticity depend on the areas of the developi[INVESTIGATOR_687954].  In 
patients with hemiplegic spasticity, one half of  the body (1 arm and 1 leg) is affected with 
spasticity.  Approximately 25% of children w ith cerebral palsy present with hemiplegic 
spasticity in which the upper limb is usually more affected than the lower limb 
(Stanley et al, 2000 ).  Spastic diplegia, pr esented in about 13% to 30% of patients with 
cerebral palsy, is characterized by [CONTACT_697968] 
(Odding et al, 2006; Stanley et al, 2000).  Although the arms are less affected, they may still 
show abnormal reflexes and reduced dexterity.  Spastic triplegia is char acterized by [CONTACT_697969] [ADDRESS_947430] common form of 
spastic cerebral palsy, aff ecting approximately 20% of pa tients.  Since both cerebral 
hemispheres are affected, intellectual impairment is common.  Patients with quadriplegia 
may also have severe dysarthria, dysphagia, a nd other comorbidities such as epi[INVESTIGATOR_697965].  Spasticity and abnormal muscle tone  contribute both to impairment of function 
and reduced longitudinal muscle growth in children with cerebral palsy ( Dunne et al, 1995 ).   
Cerebral palsy is the most common etiology a ssociated with pediat ric spasticity with a 
prevalence rate of approximately 2.5 in 1000 liv e births, a number that has increased from 
1.5 in 1000 live births 40 years ago (Odding et  al, 2006) and is considered to be the most 
severe childhood physical disability ( Beckung and Hagberg, 2002).  Essentially all patients 
with cerebral palsy have impaired motor functi on with spasticity affecting as many as 90%.  
Other less prevalent types of disorders asso ciated with pediatric spasticity include 
posttraumatic brain or spi[INVESTIGATOR_1828], multiple sclerosis, and other neurodegenerative 
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 21  
 conditions ( Hawamdeh et al, 2007 ).  All of these conditions ar e associated with significant 
morbidity and mortality and present an unmet medical need with limited treatment options.  
Equinus foot deformity is the most common (75%) form of spasticity in patients with 
cerebral palsy ( Cobeljic et al, 2009 ).  The increased muscle tone first presents as dynamic 
deformity and, if left untreated, transfor ms to fixed deformity as the child grows 
(Detrembleur et al, 2002 ).  Early treatment to prevent the development of fixed contracture is 
therefore important in the management of spasticity in this population. 
1.[ADDRESS_947431] patients are managed with a 
combination of treatment modalities, includi ng non-pharmacologic, systemic pharmacologic, 
local pharmacologic, and surgical treatments. 
Non-pharmacologic and non-surgical  treatments for spasticity aim to strengthen weakened 
muscles, weaken spastic muscles, and improve joint range of motion as well as motor 
development (Koman et al, 2004 ).  These interventions include occupational therapy (OT), 
physical therapy (PT), orthotics, splints, cas ting and other devices, or any combination of 
these methods.  PT and OT are regarded as e ssential for successful medical and surgical 
interventions (Butler and Darrah, 2001 ; Dumas et al, 2001 ) but the overall evidence 
supporting this is weak ( Lannin et al, 2006).  A recent study has demonstrated the enhanced 
effectiveness of OT used in combination with BOTOX® (botulinum toxin type A) purified 
neurotoxin complex (US Adopted Name [CONTACT_697978]), hereafter referred to as 
BOTOX ( Wallen et al, 2007 ).  
Systemic pharmacologic treatments include anti- spastic drugs such as baclofen, dantrolene, 
diazepam, scopolamine, and tizanidine ( Gracies et al, 1997 ; O’Flaherty and Waugh, 2003; 
Scheinberg et al, 2006 ; Steinbok, 2006).  The aim of systemic pharmacologic management is 
to reduce the muscle overactivity associated with  spasticity.  Mechanisms of action vary but 
the result is either a suppression of muscle excita tion or an enhancement of neural inhibition.  
Response to these medications is variable a nd unpredictable (O’Flaherty and Waugh, 2003).  
Major drawbacks of systemic anti-spastic therapy include the lack of specificity of targeting muscle groups and CNS side effects such as drowsiness, constipation, and cognitive 
impairment.  Local pharmacologic treatments include phenol or alcohol injections for 
specific chemolysis of targeted nerves.  The ma in risks of phenol are its potential to cause 
irreversible damage to the nerve and nearby [CONTACT_697970], as well as reduce sensation and cause 
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 22  
 dysesthesias and neuropathic pain ( Gracies et al, 1997).   Intrathecal baclofen is reserved for 
patients with disabling general spasticity th at is unresponsive to conservative 
pharmacotherapy (Koman et al, 2004 ). 
Orthopedic procedures such as contracture release, tendon lengthening, and tendon transfer 
can reduce spasticity symptoms that may result in improved access for hygiene and brace 
(orthotic) tolerability.  These su rgical procedures may also result in pain reduction, as well as 
reduction in bone deformity (osteotomy).  Howe ver, many forms of surgery are best delayed 
until tendons and joints have grown to a reasona ble proportion of their adult size since it is 
more difficult to predict the outcome of surg ery in younger children.  Surgical procedures 
have been reported as delayed due to the abil ity of botulinum toxin (type A) therapy to 
minimize fixed muscle shortening and soft tissu e and skeletal deformation and reduce pain 
associated with spasticity (Molenaers et al, 2006 ). 
Neurosurgical procedures include selectiv e dorsal rhizotomy and selective peripheral 
neurotomy ( Chambers, 1997; Steinbok, 2006).  Selective dorsal rhizotomy is used to treat 
severe spasticity of the lower extremities that in terferes with mobility or positioning.  It is 
usually most effective in a small number of select diplegic or qua driplegic children with 
cerebral palsy who are expected to be independent ambulators.  In children with underlying 
muscle weakness, rhizotomy can worsen rather than improve function. 
1.3 BOTOX for Management of Pediatric Spasticity 
Botulinum neurotoxin type A (BoNT-A) blocks neuromuscular conduction by [CONTACT_697971], ente ring the nerve terminals, and inhibiting the 
release of acetylcholine.  Wh en injected intramuscularly at therapeutic doses, BoNT-A 
produces localized chemical denervation of the muscle, resulting in focal muscle weakness.  
This muscle weakness is reversible through nerv e ending recovery over a period of [ADDRESS_947432] demonstrated an acceptable safety profile of 
BOTOX at the dose ranges evaluated for this patient population.  Study OCUL-118-8051, a 
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 23  
 placebo-controlled study, included 145 patients (72 BOTOX; 73 placebo) with equinus foot 
deformity who were 2 to 14 years old.  Patient s received injections of BOTOX (4 to 8 U/kg; 
note that BOTOX doses throughout this protocol  are expressed per body weight) or placebo.  
The proportion of responders based on gait pa ttern score was signi ficantly greater (p ≤ 0.05) 
in the BOTOX group compared to the placebo group at weeks 2, 8, and 12.   
Study OCUL-119-8051, an open-label multiple-treatment extension of Study 
OCUL-118-8051, included 207 patients who receiv ed injections of BOTOX at 4 U/kg.  For 
the first 2 years of the study the proportion of responders ranged from 39% to 64%.   
Study OCUL-120-8051, a placebo-controlled stud y, included 35 ambulatory patients with 
equinus foot deformity (17 BOTOX; 18 placebo)  who were 2 to 14 years old.  Patients 
randomized to BOTOX received 4 U/kg in the af fected limb.  The proportion of responders 
based on gait pattern score was significantly greater (p ≤ 0.05) in the BOTOX group 
compared to the placebo group at weeks 8 and 12.  Twenty-five of th e 35 patients entered a 
2-year, multiple-treatment open-la bel follow-up study (BTOX-121-8051).   
The fifth study (191622-021), a placebo-controlled study, included 149 patients with equinus 
foot deformity (73 BOTOX; 76 placebo) who were 2 to 8 years old.  Patients randomized to BOTOX received 4 U/kg in each affected limb (up to a maximum of 8 U/kg).  No significant 
differences in the proportion of responders ba sed on the gait pattern score were observed 
between the [ADDRESS_947433] dynamic muscle contracture of the ankle plantar 
flexors associated with equinus foot position. 
The maximum lower limb dose in a single limb se lected for this study corresponds to the 
maximum dose group (8 U/kg) from the efficacy Study 191622-111.  This dose is supported 
by [CONTACT_697972], clinical expert advice, 
published literature including consensus guidelines for botulinum toxin type A treatment of pediatric spasticity, and n onclinical toxicology data. 
The doses for lower limb treatment used in the present study ar e supported by [CONTACT_697973].  The European 
consensus paper ( Heinen et al, 2010 ) recommended a dose range of 1 to 20 U/kg with a 
maximum total dose of 400 U, rega rdless of location of injection.  The American Academy of 
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 24  
 Neurology also concluded that botulinum toxin doses ranging from 2 to 30 U/kg for 
treatment of the uppe r and lower limbs are effective and generally safe ( Delgado et al, 2010 ).  
The 2010 International Consensus Paper for bot ulinum toxin treatment in lower limb 
spasticity for children with cerebral palsy recommends a dose range of 16 to 20 U/kg for 
patients with Gross Motor Function Classi fication System – Expanded and Revised 
(GMFCS-E&R) level I to IV  without risk factors ( Love et al, 2010).  The higher dose ranges 
were based on studies allowing injections to multiple muscles (multi-level injections) across upper and lower extremities ( Heinen et al, 2006 ; Molenaers et al, 2009 ).   
Doses recommended for individual muscles are 3 to 6 U/kg for gastrocnemius, 2 to 3 U/kg 
for soleus, and 1 to 2 U/kg for tibialis posterior ( Russman et al, 2008).  In published double-
blind studies in pediatric patient s with lower limb spasticity, a dose of 2 to 8 U/kg was most 
commonly used for the gastrocnemius muscles.  The maximum dose ranged from [ADDRESS_947434] current clinical practice. 
In addition, the safety of 10 U/kg for combined  treatment of the lower limb and upper limb or 
both lower limbs in this study is also supporte d by [CONTACT_639226]-observable-adverse-effect levels 
(NOAELs) established in BOTOX toxicology studies.  In single and repeated-dose studies in 
rats, 10 and 16 U/kg were defined as NOAELs, re spectively.  In monkeys, the single-dose 
intramuscular NOAEL was determined to be  16 U/kg when administered into the 
gastrocnemius muscle.  In repeated-dose toxicity studies in monkeys involving multiple injection sites that more closely mimic clinic al use, the NOAEL was 8, 12, or 16 U/kg for 2, 
4, or 6 injection sites, respectively. 
Based on the above dose considerations, doses of up to 8 U/kg (maximum 300 U) for one 
lower limb, up to 10 U/kg (maximum 340 U) for both lower limbs, and up to 8 U/kg 
(maximum 300 U) for the upper limb (not to exceed a maximum total body dose of 10 U/kg 
or 340 U for upper and lower limbs combined) are considered to be appropriate. 
2. Study Objectives and Clinical Hypotheses  
2.1 Study Objectives 
To evaluate the long-term safety of repeated doses of BOTOX for the treatment of pediatric lower limb spasticity  
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 25  
 2.2 Clinical Hypothesis 
Repeated doses of BOTOX (up to 8 U/kg in the lower limb alone, up to 10 U/kg in a 
combination of both lower limbs, or up to 10 U/kg in a combination of upper and lower 
limbs) have an acceptable safety profile for trea ting pediatric lower limb  spasticity (with or 
without treatment in the upper limb). 
3. Study Design 
This is a multicenter, open-label study eval uating the safety of repeated treatments of 
BOTOX in dynamic muscle contracture in pediat ric patients with lowe r limb spasticity due 
to cerebral palsy.  Patients who successfu lly completed Allergan Study 191622-111 without 
major protocol deviations (eg, noncomplian ce to protocol-required procedures) may be 
eligible for enrollment in this study (rollover pati ents) if they meet the inclusion criteria and 
do not meet the exclusion criteria. 
Additionally, de novo patients (who did not particip ate in Allergan Study 191622-111) who 
meet inclusion criteria and do not meet the exclusion criteria may be enrolled in this study.  
Depending on the number of rollover patients  from Study 191622-[ADDRESS_947435] to be re -screened for the current 
study; the exit visit from St udy 191622-111 becomes the day 1 visit for this study after the 
patient signs the Study 191622-112 informed consent and assent (as applicable).  These visits 
allow up to 5 treatment cycles with  12 weeks between treatments.   
The timing of study visits and treatments is s hown in Figure 1 and Figure 2.  See Section 5.4 
for a detailed description of the treatment regi men and Section 8 for a detailed description of 
the study visits.  For this study, visits based on day 1 are referred to by “study week” and 
visits based on treatment are referred to by “treatment cycle week.” 
If the patient does not meet the retreatment criteria during the 12- to 14-week window, he or 
she may be treated any time up to study week 48 (the last opportunity for retreatment) but 
should be evaluated at least every 6 weeks (calculated from the latest treatment visit date) 
until he or she meets the retreatment criteria or until study week 48.  The exit visit will be 
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 [ADDRESS_947436] treatment. 
 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 27  
  

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 28  
 3.1 Safety Data Review Committee  
The safety of the study participants will be monitored by a Safety Data Review Committee 
(SDRC) composed of at least 2 non-Allergan ph ysicians and a study-independent statistician.  
Additional ad hoc participants (eg, physician sp ecialists) may be invited to participate in 
review meetings depending on the safety findings and required scope of expertise. 
The SDRC will conduct periodic review and a ssessments of the adverse events data 
throughout the entire duration of the study to ensure the safety of the study participants.  The 
SDRC may elect to review additional safety parameters (eg, laboratory data), or change the 
frequency of their review meetings depending upon emerging safety findings or changes in 
patient enrollment rates.   
For additional details regarding SDRC memb ership, standard operational procedures, 
frequency of review meetings, and other details, please refer to the SDRC charter.  
4. Study Population and Entry Criteria 
4.[ADDRESS_947437] dynamic muscle contracture of the ankle plantar 
flexors associated with equinus foot position. 
Patients who successfully completed Allerg an Study 191622-111 without major protocol 
deviations (eg, noncompliance to protocol-requir ed procedures) and have not experienced an 
adverse event that, in the investigator’s opi[INVESTIGATOR_1649],  may indicate an unacceptable safety risk for 
additional BOTOX treatments may be eligible for enrollment in this study.  Patients who 
became pregnant during Study 191622-111 cannot be enrolled in this study.  
Additionally, de novo patients (who did not particip ate in Study 191622-111) who meet 
inclusion criteria and do not meet exclusion criteria may be enrolled in this study. 
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 29  
 4.3 Inclusion Criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following are inclusion criteria
 for de novo patients:  
1. Male or female, 2 to 16 years and 11 months  of age (prior to 17th birthday) at day 1 
visit 
2. Minimum weight of 10 kg at th e screening and day 1 visits 
 
 
  

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 30  
  
 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4 Exclusion Criteria 
The following are criteria for exclusion from participating in the study for both rollover 
patients and de novo patients,  unless otherwise specified:  
 
 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 31  
 2. Any medical condition that may put the patien t at increased risk with exposure to 
Botulinum Toxin Type A Purified Neur otoxin Complex, including diagnosed 
muscular dystrophy (eg, Duchenne’s muscul ar dystrophy), myasthenia gravis, Eaton-
Lambert syndrome, amyotrophic lateral sclerosis, mitochondrial disease, or any other 
significant disease that might interfere with neuromuscular function 
 
 
 
 

Approval Date : 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex 
32

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 33  
  
13. Uncontrolled epi[INVESTIGATOR_002]  
 
 
  
 
 
 
 
 
 
 
 
   
 
 
 
 
  
 
  
  
 
 
 
 
 
   
19. Botulinum toxin therapy of any serotype fo r any condition within 3 months prior to 
the day 1 visit ( de novo patients only) 
 
 
  

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 34  
  
 
22. History of surgical intervention 
of the lower leg (the knee and below of the study 
limb[s]) within 12 months prior to the day1 visit ( de novo patients only) or planned 
surgical intervention of any limb(s) during the study 
 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.5 Permissible and Prohibited Medications/Treatments 
4.5.1 Permissible Medications/Treatments 
Concomitant anti-spastic medications or muscle  relaxants will be permitted during the study.  
Patients who are already on concomitant anti- spastic medications or muscle relaxants 
(eg, benzodiazepi[INVESTIGATOR_1651], oral baclofen, scopolamine [oral or patch], tizanidine, vigabatrin, or 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 35  
 dantrolene) at the time of the day 1 visit will be encouraged to remain on a stable dose and 
regimen during the study; however, dose adjust ments to their concomitant anti-spastic 
medications or muscle relaxants will be allo wed as clinically indicated.  Initiation and 
adjustment of anti-epi[INVESTIGATOR_697966].  If patient already has an 
intrathecal baclofen pump implanted, intrathe cal baclofen therapy is permitted for both de 
novo and rollover patients during the study at the investigator’s discretion. 
Patients will also be permitted to use soft splints, casts, and dynamic splints (UltraFlex®, 
DynaSplint®) during the study at the investigator’s di scretion.  However, patients should be 
asked not to wear the splint for at least 30 mi nutes before a spasticity measure at the office 
visits. 
Therapy (including OT and PT) considered nece ssary for the patient’s welfare may be given 
at the discretion of the investigator.  If the perm issibility of a specific medication/treatment is 
in question, please contact [CONTACT_78562]. 
[IP_ADDRESS] Acceptable Contraceptive Method s and Definition of Females 
of Childbearing Potential 
At the time of screening, if a female patie nt is approaching puberty but is not yet of 
childbearing potential, then the patient and/or her legally authorized representative must be 
advised that if she becomes of childbearing potential (defined as females post menarche) 
during the study, she and/or her le gally authorized representative must notify the site of this 
change.  A urine pregnancy test must be perfor med at the patient’s next scheduled visit.  
Upon receiving this notification, the site personnel must advise the patient and/or her legally 
authorized representative of the protocol requirement that any female of childbearing 
potential must use a reliable method of contraception as described below. 
For females of childbearing potential who may participate in the study, the following 
methods of contraception, if properly used, are generally considered reliable:  oral 
contraceptives, patch contraceptives, injecti on contraceptives, implantable contraceptives, 
male condom with intravaginal spermicide, diaphragm or cervical cap with spermicide, 
vaginal contraceptive ring, intrauterine device, surgical steril ization (bilateral tubal ligation 
or removal of both ovaries), vasectom ized partner, or sexual abstinence. 
The investigator and each patient (and/or her legally authorized representative) will 
determine the appropriate method of contraception for the patien t during the participation in 
the study.  The method of contraception must be  documented in the patient’s medical record 
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 36  
 and electronic case report forms (eCRFs).  At each study visit, the investigator must counsel 
female patients of childbearing potential and/or their legally authorized representatives 
regarding the importance of main taining their agreed-upon method of contraception.  A urine 
pregnancy test is required prior to each study treatment for female patients of childbearing potential. 
If a female patient of childbearing poten tial becomes pregnant during the study, the 
investigator will notify Allergan  immediately after the pregnancy is confirmed and the patient 
will be exited from the study after appropriate safety follow-up.  The investigator will (1) 
notify the patient’s physician th at the patient was being treated with BOTOX and (2) follow 
the progress of the pregnancy.  The inves tigator must document the outcome of the 
pregnancy and provide a copy of the documentation to Allergan. 
4.5.2 Prohibited Medications/Treatments 
Patients should not be permitted to initi ate the following therapy during the study: 
• Anti-spastic medications or muscle relaxa nts (eg, benzodiazepi[INVESTIGATOR_1651], vigabatrin, 
baclofen [oral or pump], scopolamine [oral or patch], tizanidine,  or dantrolene)  
Patients who enter the study on any of the above  concomitant medications should remain on 
a stable dose throughout the study to the extent possible unless j udged by [CONTACT_687973]. 
In addition, the following treatments or  therapy are not permitted during the study: 
• Botulinum toxin therapy of any serotype  (outside of the study treatment)  
• Phenol or alcohol injection to the study lower limb 
• Planned surgery in any limb(s) 
Co-administration of aminoglycosides or other agents that co uld interfere with 
neuromuscular transmission (eg, curare-like agents) s hould only be used with caution as the 
effects of toxin theoretically could be potentiated. 
The decision to administer a prohibited medicat ion/treatment is done with the safety of the 
patient as the primary consideration.  Patient s may stay in the study even if a prohibited 
medication is administered.  When possible, Allergan should be notified before the prohibited 
medication/treatment is administered. 
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 37  
 4.5.3 Special Diet or Activities 
PT/OT is an important element of the treatment a pproach in pediatric patients with spasticity.  
While no study-specific PT/OT will be  required, patients should follow 
investigator’s/therapi[INVESTIGATOR_541]’s recommendations re garding appropriate PT/OT.  PT/OT should 
remain consistent, to the extent possible, throughout the entire duration of the study. 
5. Study Treatments  
5.1 Study Treatments and Formulations 
The study treatment will be BOTOX.   
 
 
 
5.2 Methods for Blinding 
This is an open-label study, and therefore no blinding of the study medication is required. 
5.3 Method for Assignment to Treatment Groups 
At the screening visit, after the de novo patient and/or legally aut horized representative has 
signed the informed consent and minor assent (as applicable), the site will call the interactive 
voice response system (IVRS) or log on to th e interactive web response system (IWRS) to 
obtain the patient number that will serve as  the patient identifi cation number on all study 
documents.  At the study day 1 visit for both de novo and rollover patients, the site will 
access the IVRS/IWRS to enroll the patient.  Ro llover patients transitioning from Allergan 
Study 191622-111 will maintain the same patient number that was assigned in that prior 
study. 
Study medication will be labeled with medica tion kit numbers.  At day 1 and at all 
retreatment visits where the patient qualifies fo r reinjection, sites will call the IVRS or log 
onto the IWRS to obtain specific study medicat ion kit numbers for each patient.  Sites will 
dispense study medication according to the IVRS /IWRS instructions.  Sites will receive an 
IVRS/IWRS confirmation notification for each tr ansaction.  All notifications must be 
maintained with the study source documents. 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 [ADDRESS_947438] 4 U/kg in the study lower limb( s) every [ADDRESS_947439] treatment cycle, de novo patients are to receive a total of 8 U/kg (not to 
exceed 300 U) either in a single study lower limb or divided between both study lower limbs 
only for diplegic patients.  
5.4.2 Treatment Cycle 1 for Rollover Patients  
Patients transitioning from Study 191622-111 will be allowed to receive injections in the 
upper limb, the lower limb, or a combination of upper and lower limbs in all cycles, 
including treatment cycle 1.   
   
 
5.4.3 Treatment Cycles 2 Through 5 for All Patients (Rollover and 
De Novo)  
For treatment cycles 2 through 5, the maximu m dose for treatment only in a single lower 
limb or upper limb remains the same as for treatment cycle 1; the maximum dose for 
combined upper and lower limbs or for both lo wer limbs only for diplegic patients can be 
increased to 10 U/kg (not to exceed 340 U) .  Dose limitations by [CONTACT_697974]: 
• up to 8 U/kg (not to exceed 300 U) for each treatment session if administered only to 
one lower limb or only to one upper limb or 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential  Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 39  
 • up to 10 U/kg (not to exceed 340 U) if admi nistered to both lower limbs for diplegic 
patients or  
• up to 10 U/kg (not to exceed 340 U) if ad ministered to a combination of upper and 
lower limbs 
The dose for each muscle and the total dose wi ll be determined by [CONTACT_093].   
 
 
 
 
Approval  Date:  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 40  
  

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 41  
  5.4.4 Treatment Regimen/Dosage Adjustment 
For all patients enrolled, the dose should be calculated based on patient’s body weight in 
kilograms measured on the day of each treatmen t/retreatment visit.  For purposes of dose 
calculation, the patient’s weight will be rounded to the nearest whole kilogram.  If the dose 
by [CONTACT_18694] (U/kg x body weight) exceeds the per-muscle dose, the total maximum dose 
for the lower limb(s) or upper limb, or the total body maximum units, then the maximum 
dose (“not to exceed” units) should be used.  Th e dose for each injection site should not 
exceed 50 U. 
[IP_ADDRESS] Retreatment Criteria 
Patients may be reinjected if they meet all of the following criteria on the day of retreatment 
prior to the injection:   
 
 
b) At least [ADDRESS_947440] study treatment of BOTOX 
c) Did not experience the following since previous treatment: 
• adverse events of compromised respi[INVESTIGATOR_4806], aspi[INVESTIGATOR_51520], difficulty 
swallowing, or clinically significant exce ssive salivation.  Patients who have 
experienced these adverse events must not receive any further study 
treatments. 
• an adverse event or excessive weakness that, based on the investigator’s clinical judgment, indicates an unacceptable safety risk for additional BOTOX 
treatments.  Patients may be re-evaluated for retreatment once the adverse 
event or muscle weakness is resolved.   
•  
 
 
d) A negative urine pregnancy test for female patients of childbearing potential. 
  
 
 
 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 42  
   
  
  
 
 
 
 
 
 
 
 
5.5 Storage of Study Medications/Treatments 
The study medication must be stored in a secu re area and administered only to patients 
entered into the clinical study, at no cost to the patients, in accordance with the conditions 
specified in this protocol. 
 
 
 
 
5.6 Preparation of Study Medications/Treatments 
BOTOX (100 U vial) will be reconstituted with 2 mL of preservative-free saline. 
5.7 Treatment Administration 
Muscles localization techniques such as e-s timulation, sonography, and/or electromyography 
(EMG) are recommended for this study.  Moto r endplate targeting inje ction techniques are 
recommended ( Van Campenhout and Molenaers, 2011). 
The study medication may be administered in  conjunction with appropriate anesthesia 
according to each investigator’s standard practice.  Patients who are planning to undergo 
general anesthesia should be carefully examined by [CONTACT_697975]. 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 43  
  6. Response Measures and Summary  of Data Collection Methods 
  
  
   
  
  
  
 
  
 
  
6.1.1 Primary Efficacy Measure 
No primary efficacy measure is identified. 
  
• Adverse events 
  
  
  
  
  
  
 
  
6.2 Examination Procedures, Tests,  Equipment, and Techniques  
The procedures are described in Attachment 12.1.   

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 44  
    
 
 
  
 
 
   
  
  
  
 
  
 
 
  
  
  
  
  
 
  
  
  
  
 
6.4 Summary of Methods of Data Collection 
An IVRS/IWRS will be used to assign patient numbers for de novo patients and to manage 
study medication inventory.  Data will be coll ected using eCRFs via a validated electronic 
data capture system (EDC).  Source documents w ill be used and stored at the sites, and may 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 45  
  include a patient’s medical records, hospi[INVESTIGATOR_452095], clinical charts, pati ent chart, copy of the 
EDC file, as well as the results  of diagnostic tests such as laboratory tests, ultrasounds, 
x-rays, and ECGs.   
 
 
 
  
A central laboratory will be used for the anal ysis of all blood samples.  Blood samples for 
immunogenicity tests will be shipped by [CONTACT_2237], anal yzed by a specialty 
laboratory using validated assays, and the data will be transferred to Allergan or enter to the 
eCRF. 
7. Statistical Procedures 
The database lock will occur when all patien ts have completed the study and all data except 
immunogenicity data have been cleaned.  A detaile d analysis plan will be generated prior to 
the database lock.  All planned analyses will be performed after the database is locked. 
7.1 Analysis Populations 
Safety data will be analyzed on the basis of all treated patients based on the treatment received, defined as the safety population.   
 
 
7.2 Collection and Derivation of Pr imary and Secondary Efficacy 
Assessments 
 
 
 
 
 
 
 
 
  The applicable scores, applicab
le changes from baseline to 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 [ADDRESS_947441] injection in this 
study will be derived. 
   
   
  
  
 
  
  
  
  
 
  
7.2.2 Primary Efficacy Variable(s) 
No primary efficacy variable is identified. 
7.[ADDRESS_947442] ing unless otherwise specified. 
  
 
 
 
 
 
 
   

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 47  
   
 
 
 
 
7.3.2 Safety Analyses 
Safety variables including the incidence of adverse events,  
 
 
 
 
  
The incidence of adverse events will be ta bulated by [CONTACT_687977].   
 
 
 
 
 
 
 
 
 
 
   
 
   
 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 48  
  7.4 Subgroup Analyses 
The safety analyses for all adverse events will  be presented by [CONTACT_654],  previous exposure to 
botulinum toxin, and type of anesthesia, if appropriate.   
7.5 Sample Size Calculation 
Approximately 350 patients will be enrolled.  The sample size was determined empi[INVESTIGATOR_687959]. 
7.6 Interim Analyses 
Periodic safety summaries will be provided to the SDRC for review.  In addition, periodic 
safety and efficacy data summaries may be ge nerated for the purpose of study monitoring.  
An interim safety analysis may be perf ormed for regulatory filing, if needed. 
  
 
 
  
   
  
 
 
  
 
 
 
 
 
 
   
 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 49  
   
   
  
 
 
 
 
   
   
 
 
 
 
   
 
  
  
  
 
 
 
   
 
  
 
  
  

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 50  
    
 
 
  
  
 
   
  
 
 
  
  
  
  
  
 
 
 
 
  
  
 
  
  
 
 
 
 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 51  
     
  
  
  
 
  
 
 
   
  
  
 
 
 
  
   
  
  
   
  
 
  
  
  
 . 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 52  
    
 
  
  
   
  
 
 
  
 
 
 
  
 
    
  
  
 
  
 
  
  
  
  
 
  

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 53  
    
 
   
 
 
  
 
 
  
 
   
  
 
 
 
 
 
 
   
  
 
  
  
  
 
 
  
  

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 54  
    
  
  
  
  
  
 
  
  
 
  
  
   
  
 
   
  
  
  
  
 
  
 . 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 55  
    
 
 
  
  
  
 
 
  
  
  
  
  
   
  
  
   
  
 
  
  
 
  
  
   

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 56  
    
 
  
 
    
  
  
  
  
 
 
 
  
 
 
  
   
  
 
 
  
  
  
 
 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 57  
    
  
 
  
 
  
 
    
  
  
  
  
  
  
 
 
  
 
  
  
   
  
 
 
  

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 58  
    
 
  
  
 
  
8.4 Instructions for the Patients 
Patients/caregivers will be instructed to stric tly follow the study visit schedule and report any 
changes in condition to the investigative site.   
8.5 Unscheduled Visits 
Unscheduled visits can be performed and at the discretion of the investigator eg, for safety 
concerns or for retreatment evaluation (if time si nce the last study treatme nt has been at least 
12 weeks).  If the patient is eligible and receiv es study treatment, this visit becomes a 
treatment visit.  Additional examinations may be performed as necessary to ensure the safety 
and well being of patients during the study.  eCRFs will be completed for each unscheduled 
visit.   
8.[ADDRESS_947443] baseline visit, patients/caregive rs will be questioned on concomitant medication 
use and procedures or test since the last visit to ensure protocol compliance.   
8.7 Early Discontinuation of Patients 
Patients may voluntarily withdraw from the study at any time or may be withdrawn at the 
discretion of the investigator and Allergan due to  clinically significant findings including, but 
not limited to, adverse events and clinical la boratory abnormalities.  Notification of early 
patient discontinuation from the study and the reason for discontinuation will be made to Allergan and be clearly documented on the appropriate eCRF.  Patients who wish to 
discontinue future treatments should be asked to consider returning for the study exit visit.  

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 [ADDRESS_947444] visit for the patient will be considered  the study exit visit.  Procedures identified in 
Table 1 and Table 2 for the exit/early terminati on visit will be performe d if the study exit visit 
occurs earlier than study week 48.   
8.8 Withdrawal Criteria  
Patients will be withdrawn from the study if they: 
• develop a medically significant hypersensitivity reaction to the study drug  such as 
angioedema or anaphylaxis, or 
• become pregnant during the study 
Patients will continue to be followed up for safe ty until the issue is resolved or the condition 
is stabilized.  Please see Section [IP_ADDRESS] for follow-up for patients who become pregnant 
during the study. 
Patients have the right to withdraw from the study at any time and for any reason without 
prejudice to his or her future medical care by [CONTACT_116323].  The 
investigator and Allergan also have the right to withdraw a patient from the study at any time 
for any reason. Patients who withdraw from the study will not be replaced.  
8.9 Study Termination 
The study may be stopped at his/he r study site at any time by [CONTACT_535394].  Allergan 
may stop the study (and/or the study site) for a ny reason with appropriate notification.  
9. Adverse Events  
Adverse events occurring during the study will be recorded on an adverse event eCRF.  If 
adverse events occur, the first concern will be the safety of the study participants.  
9.[ADDRESS_947445] a causal 
relationship with this treatment.  An advers e event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), sympto m, or disease temporally 
associated with the use of a medicinal (investi gational) product, whether or not related to the 
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 60  
  medicinal (investigational) product.  In additi on, during the screening period, adverse events 
will be assessed regardless of the administration of a pharmaceutical product.   
Adverse events will be assessed and documented,  as appropriate, throughout the study (ie, 
after informed consent has been obtained).  At each visit, the investigator will begin by 
[CONTACT_687979] t/caregiver a general, non-directed question 
such as “How have you been feeling since the last visit?”  Directed questioning and examination will then be done as appropriate.  All reported adverse events will be 
documented on the appropriate eCRF.   
9.1.2 Serious Adverse Event 
A serious adverse event is any adverse event occu rring at any dose that results in any of the 
following outcomes:  death, a life-threatening adverse event, inpatient hospi[INVESTIGATOR_249589], a persistent or signifi cant disability/in capacity, or a 
congenital anomaly/birth defect.  Important medi cal events that may not result in death, be 
life-threatening, or require hospi[INVESTIGATOR_3767] a serious adverse event when, 
based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to  prevent one of the outcomes listed in this 
definition.  (See Section 9.3 for procedur es for reporting a serious adverse event.) 
Note:  Allergan considers all cancer adverse even ts as serious adverse events.  In addition, 
Allergan considers any abortion (spontaneous or nonspontaneous) as a serious adverse event. 
9.1.[ADDRESS_947446] be  completed using the following definitions as 
guidelines: 
Mild Awareness of sign or symptom, but easily tolerated 
Moderate Discomfort enough to cause interference with usual activity 
Severe Incapacitating with inability to work or do usual activity Not applicable In some cases, an advers e event may be an ‘all or nothing’ finding 
which cannot be graded 
 
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 61  
  9.1.4 Relationship to Study Drug or Study Procedure 
A determination will be made of the relations hip (if any) between an adverse event and the 
study drug or study procedure, as applicable.  A causal relationship is present if a 
determination is made that there is a reasonable possibility that the adverse event may have 
been caused by [CONTACT_335851].   
9.[ADDRESS_947447] be recorded on the appropriate eCRF. 
All adverse events that are drug- related and unexpected (not listed as treatment-related in the 
current Investigator’s Brochure) must be re ported to the governing IRB/IEC as required by 
[CONTACT_1201]/IEC, local regulations, and the governing health authorities.  Any adverse event that 
is marked “ongoing” at the exit visit must be followed-up as appropriate. 
9.3 Procedures for Reporting a Serious Adverse Event 
Any serious adverse event occurring during the study period (beginning with informed 
consent) and for at least [ADDRESS_947448] supply Allergan 
and the IRB/IEC with any additional requested in formation (eg, autopsy reports and terminal 
medical reports).  
In the event of a serious advers e event, the investigator must: 
1. Notify Allergan immediately by [CONTACT_687980] 
(contact [CONTACT_249620] 1 of  the serious adverse event form); phone 
numbers and relevant Allergan personnel c ontacts are also on the front page of 
protocol. 
2. Obtain and maintain in his/her files all pe rtinent medical records, information, and 
medical judgments from colleagues who assi sted in the treatment and follow-up of 
the patient. 
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 62  
  3. Provide Allergan with a complete, written case history (adverse event report form) 
which includes a statement as to whether th e event was or was not related to the use 
of the investigational drug. 
4. Promptly inform the governing IRB/IEC of the serious adverse event as required by 
[CONTACT_1201]/IEC, local regulations, and the governing health authorities. 
10. Administrative Items 
This protocol is to be conducted in accord ance with the applicable  Good Clinical Practice 
(GCP) regulations and guidelines, eg, the In ternational Conference on Harmonisation (ICH) 
Guideline on GCP. 
10.1 Protection of Human Subjects 
10.1.1 Compliance with Informed Co nsent Regulations (US 21 CFR 
Part 50) and Relevant Country Regulations 
Written informed consent is to be obtained from  each patient prior to enrollment into the 
study, and/or from the patient’s legally authorized representative.  If the patient is under the legal age of consent, the consen t form must be signed by [CONTACT_697976].  
Written parental/legally authorized representative  informed consent in addition to a separate 
written minor consent and/or assent (in acco rdance with any applicable state and local 
laws/regulations) are required for each minor study patient prior to study enrollment or any 
study-related procedures in the study. 
10.1.2 Compliance With IRB or IEC Regulations 
This study is to be conducted in accordance with IRB regulations (US 21 CFR Part 56.103) 
or applicable IEC regulations.  The inves tigator must obtain a pproval from a properly 
constituted IRB/IEC prior to init iating the study and re-approval or review at least annually.  
Allergan is to be notified immediately if the re sponsible IRB/IEC has been  disqualified or if 
proceedings leading to disqualification have begun.  Copi[INVESTIGATOR_28078]/IEC correspondence 
with the investigator should be provided to Allergan. 
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 [ADDRESS_947449] ance with the applicable GCP regulations and 
guidelines.  
10.1.4 Compliance With Electronic Reco rds; Electronic Signatures 
Regulations (US 21 CFR Part 11) 
This study is to be conducted in compliance with the regulations on electronic records and 
electronic signature. 
10.[ADDRESS_947450] not implement any devia tion from or changes of the protocol without 
approval by [CONTACT_535398]/favorable opi[INVESTIGATOR_120973]/IEC of a protocol amendment, except wher e necessary to eliminate immediate hazards 
to study patients, or when the changes involve on ly logistical or admini strative aspects of the 
study (eg, change in monitors, change of telephone numbers). 
10.3 Patient Confidentiality 
A report of the results of this study may be published or sent to the appropriate health 
authorities in any country in which the study drug may ultimately be marketed, but the 
patient’s name [CONTACT_249626].  The patient’s name [CONTACT_249627], Allerg an, or the governing hea lth authorities or the 
FDA if they inspect the study records.  Appr opriate precautions will be taken to maintain 
confidentiality of medical reco rds and personal information. 
10.3.1 Patient Privacy 
Written authorization (US sites only), data protection consent (European sites only), and 
other documentation in accordance with the rele vant country and local privacy requirements 
(where applicable) is to be obtained from each patient prior to enrollment into the study, and/or from the patient’s legally authorized representative in accordan ce with the applicable 
privacy requirements (eg, the Health Insurance Port ability and Accountab ility Act Standards 
for Privacy of Individually Iden tifiable Health Information (“HIPAA”), European Union Data 
Protection Directive 95/46/ EC [“EU Directive”]). 
In accordance with HIPAA requirements, additional purposes of this study include the 
following: 
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 64  
  •  to publish anonymous patient data from the study; and  
•  to create and maintain a data repository 
10.4 Documentation 
10.4.1 Source Documents 
Source documents may include a patient’s medical records, hospi[INVESTIGATOR_1332], clinic charts, the 
investigator’s patient study file s, as well as the results of di agnostic tests such as X-rays, 
laboratory tests, and electrocar diograms.  The investigator’s copy of the case report forms 
serves as part of the investigator’s reco rd of a patient’s study-related data.   
The following information should be entere d into the patient’s medical record: 
• Patient’s name 
• Patient’s contact [CONTACT_3031] 
• The date that the patient entered the study , patient number, and medication kit number 
• The study title and/or the protocol number  of the study and the name [CONTACT_502190] 
• A statement that informed consent and/ or assent, if applicable was obtained 
(including the date).  A statement that wr itten authorization (US sites only), data 
protection consent (EU sites on ly), or other country and lo cal subject patient privacy 
required documentation for this study ha s been obtained (i ncluding the date). 
• A statement that patient meets all the inclus ion criteria and does not meet any of the 
exclusion criteria.  If a patient does not qualify for the study, a screen failure reason 
should be noted. 
• Dates of all patient visits 
• Medical and surgical history  
• Documentation of results of all procedures conducted during the course of the trial, 
including the dose determination process and reason(s) why patient did not meet 
retreatment criteria.  
  
• For sites performing the Edinburgh Visual Gait score, the videotape 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 65  
  • The results of laboratory tests performed by [CONTACT_3433] e site (eg, results of hematology, serum 
chemistry, HbA1c, urine pregnancy, and immunogenicity tests) 
• All concurrent medications (list all pr escription, non-pres cription and herbal 
medications being taken 3 months prior to or at the time of enrollment).  At each 
subsequent visit, changes to  the list of medications and concurrent procedures should 
be recorded. 
• Occurrence and status of  any adverse events 
• The date the patient exited the study, a nd a notation as to whether the patient 
completed the study or reason for discontinuation 
10.4.2 Case Report Form Completion 
The investigator is responsible for ensuring that  data are properly recorded in each patient’s 
eCRF and related documents.  An investigator who has signed the protocol signature [CONTACT_687988] (as indicated in the eCRFs) to ensure that the observations and findings are recorded in the eCRFs correctly and completely.  The eCRFs 
are to be completed in a timely manner. 
10.4.3 Study Summary 
An investigator’s summary will be provided to Allergan within a short time after the 
completion of the study, or as designated by [CONTACT_287447].  A summary is also to be provided to 
the responsible IRB/IEC. 
10.4.[ADDRESS_947451].  These documents 
should be retained for a longer period, however , if required by [CONTACT_941] a pplicable re gulatory 
requirement(s) or if needed by [CONTACT_78562]. 
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 66  
  In addition, for countries not falling within th e scope of the ICH guidelines, local regulatory 
requirements should be followed regarding the re tention of clinical study documentation. 
Allergan requires that it be notified in writi ng if the investigator wishes to relinquish 
ownership of the data so that mutually agreed-u pon arrangements can be made for transfer of 
ownership to a suitably qua lified, responsible person. 
10.5 Labeling, Packaging, and Return or Disposal of Study 
Medications/Treatments 
  
  
 
 
10.5.[ADDRESS_947452] 
supervision of an investigator. 
10.5.3 Return or Disposal of Study Medications/Treatments and/or 
Supplies 
All clinical study medications/treatments and/or  supplies will be returned to Allergan or 
Allergan designee for destruction. 
10.[ADDRESS_947453] 
on-site visits to review, audit and copy study- related documents.  These representatives will 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 67  
  meet with the investigator(s) and appropriate staff at mutua lly convenient times to discuss 
study-related data and questions. 
10.7 Handling of Biological Specimens 
Laboratory specimens for blood chemistry panel,  hematology and HbA1c, will be sent to a 
centralized clinical la boratory with certification from a recognized accreditation agency (eg, 
College of American Pathology [CAP] or C linical Laboratory Improvement Amendments 
[CLIA] certification) to be assayed using validated methods.  Samples for immunogenicity 
will be sent to the central laboratory for tempor ary storage and will then be sent to a specialty 
laboratory for analysis.  Allergan shall have  full ownership rights to any biological 
specimens/samples derived from the study.  Appr oximately 14 mL of blood is estimated to be 
collected at a given visit for children 15 kg a nd above (7 mL for hematology and chemistry 
and 7 mL for immunogenicity testing).  Approxi mately [ADDRESS_947454] joint cooperation betw een multiple investig ators and sites and 
Allergan personnel.  Authorship will be establis hed prior to the writing of the manuscript.  As 
this study involves multiple centers, no individu al publications will be allowed prior to 
completion of the final report of the multicente r study except as agreed with Allergan.   
10.9 Coordinating Investigator 
A signatory Coordinating Investigator [INVESTIGATOR_535354]. 
11. References  
Barry MJ, Van Swearingen JM, Albright AL.  Reliability and responsiveness of the Barry-
Albright Dystonia scale.  Dev Med Child Neurol. 1999;41:404-411. 
Beckung E, Hagberg G.  Neuroimpairment, activit y limitations, and participation restrictions 
in children with cerebral palsy.  Dev Med Child Neurol. 2002;44:309-316. 
Bohannon RW, Smith MB.  Interrater reliability of a modified  Ashworth scale of muscle 
spasticity. Phys Ther. 1987;67:206-207. 
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 68  
  Butler C, Darrah J.  Effects of neurodevelopmen tal treatment (NDT) for cerebral palsy:  an 
AADPDM evidence report.  Dev Me d Child Neurol. 2001;43:778-790. 
Chambers HG.  The surgical treatment of spas ticity.  Muscle Nerve Suppl. 1997;6:S121-128. 
Cobeljic G, Bumbasirevic M, Lesic A, Bajin Z.  The management of spastic equinus in 
cerebral palsy. Orthop Trauma 2009;23:201-209. 
Delgado MR, Hirtz D, Aisen M, Ashwal S, Fe hlings DL, McLaughlin J, et al.  Practice 
parameter:  pharmacologic treatment of spasticity in children and adolescents with cerebral 
palsy (an evidence-based review ).  Neurology. 2010;74:336-343. 
Detrembleur C, Lejeune TM, Renders A, Van Den Bergh PY.  Botulinum toxin and short-
term electrical stimulation in the treatment of equinus in cerebral palsy.  Mov Disord. 
2002;17:162-169. 
Dumas HM, O’Neil ME, Fragala MA.  Expert consensus on physical therapi[INVESTIGATOR_687961] A injection for children with cerebral palsy.  Pediatr Phys Ther. 
2001;13:122-132. 
Dunne JW, Heye N, Dunne SL.  Treatment of chr onic limb spasticity with botulinum toxin A.  
J Neurol Neuros Psy. 1995;58:232-235. Gracies JM, Elovic E, McGuire J, Simpson D.  Traditional pharmacological treatments for 
spasticity.  Part 1:  Local treatmen ts.  Muscle Nerve Suppl. 1997;7:S61-S91. 
Hawamdeh ZM, Ibrahim AI, Al-Qudah AA.  Long- term effect of botulinum toxin (A) in the 
management of calf spasticity in children with diplegic cerebral palsy.  Eura Medicophys. 2007;43:311-318. 
Heinen F, Desloovere K, Schroeder AS, Berweck S, Borggraefe I, van Campenhout A, et al.  
The updated European Consensus 2009 on the use of botulinum toxin for children with 
cerebral palsy.  Eur J Paediatr Neurol. 2010;14:45-66. 
Heinen F, Schroeder AS, Fietzek U, Berweck S.   When it comes to botulinum toxin, children 
and adults are not the same: multimuscle op tion for children with cerebral palsy.  Mov 
Disord. 2006;21:2029-2030. 
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 69  
  Jethwa A, Jonathan M, Macarthur C, Knights S, Fehlings T, Fehlings D.  Development of the 
Hypertonia Assessment Tool (HAT): a discrimi native tool for hypertonia in children.  Dev 
Med Child Neurol. 2010;52:e83-e87.  
Koman IA, Smith BP, Shilt JS.  Cerebral palsy.  Lancet. 2004;363:1619-1631.   
Lance JW.  Symposium synopsis.  In:  Feldmann RG, Young RR, Koella WP, eds.  Spasticity 
disordered motor control.  Chicago, Illinoi s:  Year Book Medical Publishers; 1980:485-494. 
Lannin N, Scheinberg A, Clark K.  AACPDM systematic review of the effectiveness of 
therapy for children with cerebral palsy after botulinum toxin A injections.  Dev Med Child 
Neurol. 2006;48:533-539. 
Love SC, Novak I, Kentish M, Desloovere K, Hein en F, Molenaers G, et al.  Botulinum toxin 
assessment, intervention, and after-care for lower limb spasticity in children with cerebral 
palsy: international consensus statement.  Eur J Neurol. 2010;17(Suppl 2):9-37. 
Love SC, Valentine JP, Blair EM, Price CJ, Cole  JH, Chauvel PJ.  The effect of botulinum 
toxin type A on the functional ability of the child with spastic hemiplegia: a randomized 
controlled trial.  Eur J Neurol. 2001;8(Suppl 5):50-58. 
Molenaers G, Desloovere K, Fabry G, de Cock P.  The effects of quantitative gait assessment 
and botulinum toxin A on musculoskeletal surgery in children with cerebral palsy.  J Bone 
Joint Surg. 2006;88:161-170. 
Molenaers G, Schörkhuber V, Fagard K, Van Camp enhout A, De Cat J, Pauwels P, et al.  
Long-term use of botulinum toxin type A in  children with cerebral palsy: treatment 
consistency.  Eur J Paediatr Neurol. 2009;13:421-429. Odding E, Roebroeck ME, Stam HJ.  The ep idemiology of cerebral palsy: incidence, 
impairments and risk factors.  Disabil Rehabil. 2006;28:183-191. O’Flaherty S, Waugh MC.  Pharmacologic management of the spastic and dystonic upper 
limb in children with cerebral palsy.  Hand Clin. 2003;19:585-589. 
Palisano R, Rosenbaum P, Bartlett D, Livings ton M.  GMFCS – E&R: Gross motor function 
classification system expanded and revised.  2007. Available from: 
http://motorgrowth.canchild.ca/en/GMFCS/resources/GMFCS-ER.pdf. 
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 70  
  Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al.  The 
Columbia- Suicide Severity Rating Scale (C-SSRS) :  Initial validity and internal consistency 
findings from three multi-site studies with adolescents and adults.  Am J Psychiatry.  2011;168:1266-1277. 
Read HS, Hazlewood ME, Hillman SJ, Prescott  RJ, Robb JE.  Edinburgh Visual Gait Score 
for use in cerebral palsy.  J Pediatr Orthopaed.  2003;23:296-301. Rodda J, Graham HK.  Classi fication of gait patterns in spastic hemiplegia and spastic 
diplegia: a basis for a management algorithm.   Eur J Neurol. 2001;8 (Suppl. 5):98-108. 
Russman BS, Tilton AH, Gormley Jr ME.  Cerebral  palsy:  a rational approach to a treatment 
protocol and the role of botulinum toxin in tr eatment.  In:  Brashear A, Mayer NH, eds.  
Spasticity and other forms of muscle overac tivity in the upper motor neuron syndrome.  
Etiology, evaluation, management and the role of botulinum toxin.  [LOCATION_001], [LOCATION_001]:  
WeMove; 2008:  Chapter 12. 
Scheinberg A, Hall K, Lam LT, O’Flaherty S.  Or al baclofen in children with cerebral palsy:  
A double-blind cross-over pi[INVESTIGATOR_799].  J Paediatr Child Health. 2006;42:715-720. 
Stanley F, Blair E, Alberman E.  Cerebral Palsy: epi[INVESTIGATOR_687962].  Clinics 
in Developmental Medicine, No 151. London,  England: Mac Keith Press; 2000:3-15. 
Steinbok P.  Selection of treatm ent modalities in children with  spastic cerebral palsy.  
Neurosurg Focus. 2006;21:1-8. 
Van Campenhout A, Molenaers G.  Localization of the motor endplate zone in human 
skeletal muscles of the lower limb: anatomical guidelines for injection with botulinum toxin.  
Dev Med Child Neurol. 2011;53(2):108-119. 
von Baeyer CL, Spagrud LJ.  Systematic review  of observational (behavioral) measures of 
pain for children and adolescents aged 3 to 18 years.  Pain. 2007;127:140-150.  
Wallen M, Waugh M-C, O’Flaherty S.  Func tional outcomes of intramuscular botulinum 
toxin type A and occupational therapy in the upp er limbs of children with cerebral palsy:  
a randomized controlled trial.  Arch Phys Med Rehab. 2007;88:1-10. 
 
 
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 71  
  12. Attachments 
   
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 72  
   
 
 
     
   
   
    
    
     
    
      
   
 
  
 
 
 
 
  
 
 
 
   
     
  
 
 
 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 73  
     
  
 
 
 
 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 74  
   
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
    
 
 
 
  
 
 
  
  
 
  
 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 75  
    
 
  
 
 
  
  
 
 
 
 
 
 



$SSURYDO'DWH 
-DQ$OOHUJDQ&RQILGHQWLDO 3URWRFRO$PHQGPHQW
%272;%RWXOLQXP7R[LQ7\SH$3XULILHG1HXURWR[LQ&RPSOH[ 

  


 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 77  
    
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
  
  
 
 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 78  
    
 
  
 
 
  
  
 
 
  
 
 
 
   
 
 
 
 
 
 
 
 
  
 
 
   
 
 
 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 79  
   
 
  
 
 
 
 
 
 
 
  
 
  
 
 
 
  
 
 
   
 
 
 
 
 
 
 
  

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 80  
   
  
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 81  
   
  
 
  
 
 
 
 
 
 
 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 82  
  12.2 Package Insert/Summary of Product Characteristics 
The appropriate package insert or Summary of Product Characteristics will be supplied to 
investigators in countries where the product is marketed. 
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 83  
  12.3 Glossary of Abbreviations  
Term/Abbreviation Definition 
AFO ankle foot orthosis 
   
BoNT-A botulinum neurotoxin type A 
BOTOX® Botulinum Toxin Type A Purified Neurotoxin Complex (US 
adopted name [CONTACT_697979]), referred to as BOTOX 
CFR Code of Federal Regulations (US) 
  
CNS central nervous system 
  
D day 
ECG electrocardiogram 
eCRF electronic case report form 
EDC electronic data capture 
ELISA enzyme-linked immunosorbent assay 
EMG electromyography 
EU European Union 
GCP Good Clinic al Practices 
  
 
   
HbA1c glycosylated hemoglobin 
HIPAA Health Insurance Portability and Accountability Act Standards for 
Privacy of Individually Identifiable Health Information 
ICH International Conference on Harmonisation 
IEC Independent Ethics Committee 
IRB Institutional Review Board 
ITT intent-to-treat 
IVRS interactive voice response system 
IWRS interactive web response system 
  
   
NA not applicable 
No. number 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 [ADDRESS_947455] level 
OT occupational therapy 
PT physical therapy 
Scrn screening 
SDRC Safety Data Review Committee 
Tx treatment 
U unit, corresponding to the median lethal dose (LD 50) in mice 
US [LOCATION_002] 
V1 slow velocity 
V3 fast velocity 
Wk week 
 
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 85  
  12.4 Protocol Amendment 1 Summary 
Title:  BOTOX® Treatment in Pediatric Lower Limb Spasticity:  Open-label Study 
Protocol 191622-112, Amendment 1 
Date of Amendment:  30 March 2012 
Amendment Summary 
This summary includes changes made to Protocol 191622-112 (02 December 2011) to 
provide clarifications, updated in formation, and corrections.   
Following is a summary of content-oriented changes that were made to each section of the protocol, and a brief rationale for these change s.  Minor editorial a nd document formatting 
revisions have not been summarized. 
Section(s) Revision Rationale 
Title page Added EudraCT number and 
changed Allergan Medical 
Safety Physician.  Updated information. 
 
 
 
 
 
 
 
  
 
  
 
 
 
  
 
  
 
  
 
  
 
10.7, Handling 
of Biological 
Specimens Revised approximate volume of 
blood collection for hematology 
and chemistry regardless of weight from 5 to 7 mL and total for children 15 kg and above 
from 12 to 14 mL. Based on the revised central laboratory 
(Covance) requirements. 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 86  
  Section(s) Revision Rationale 
 
 
  
  
 
  
  
 
 
 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 87  
  12.5 Protocol Amendment 2 Summary 
Title:  BOTOX® Treatment in Pediatric Lower Limb Spasticity:  Open-label Study 
Protocol 191622-112, Amendment 2 
Date of Amendment:  29 November 2012 
Amendment Summary 
This summary includes changes made to Protocol 191622-112 Amendment 1 (e-signature 
[CONTACT_568] 02 April 2012) to provide clarifications and corrections.   
Following is a summary of content-oriented changes that were made to each section of the 
protocol, and a brief rationale for these changes.  Underlining is used to identify wording that 
has been added and strikethrough for wording th at has been deleted.  Minor editorial and 
document formatting revisions have not been summarized. 
Section(s) Revision Rationale 
Summary Changes corresponding to those 
identified below in the body were 
made to the Summary section. For consistency within the protocol 
Tables 1 and 2, Schedules 
  
 
 
  
1.4, Dose Justification 2.2, Clinical Hypothesis 5.4, Treatment Regimen and Dosing Table 3 Added wording for a combination of both lower limbs for diplegic patients  Allows a dose up to 10 U/kg and not to exceed 340 U to be injected during treatment cycles 2 to 5 when both lower limbs are treated 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 88  
  Section(s) Revision Rationale 
1.4, Dose Justification Second paragraph: 
The maximum lower limb dose in a 
single limb  doses selected for  in 
this study corresponds  to the 
maximum  high dose group (8 U/kg) 
from the efficacy Study 191622-
111.  This dose is  These doses are  
supported by [CONTACT_697977], clinical expert advice, published literature including consensus guidelines for botulinum toxin type A treatment of pediatric spasticity, and nonclinical 
toxicology data. For clarification 
3, Study Design Replaced details regarding dosing 
with a cross reference to 
Section 5.4, Treatment Regimen and Dosing To consolidate dosing information in a clearly designated section 
4.4, Exclusion Criteria Cha nged #23 regarding history of 
fracture in the study upper limb within 12 months from “prior to the screening visit” to “prior to the day 1 visit.” For consistency with other criteria 
4.5.2, Prohibited Medications/Treatments Added to the wording that requires a patient to remain on a stable dose of anti-spastic medications:  to the 
extent possible unless judged by [CONTACT_687982] .  For clarification 
5.3, Method for Assignment to Treatment Groups Added At the study day 1 visit for 
both de novo and rollover, the site 
will access the IVRS/IWRS to 
enroll the patient ; For clarification 
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 89  
  Section(s) Revision Rationale 
5.4, Treatment Regimen 
and Dosing At the beginning of 5.4, replaced similar wording that was in 5.4.2 and 5.4.3 with:  If a patient meets 
the retreatment criteria, including 
no indication of an unacceptable 
safety risk, and it is considered to 
be clinically appropriate by [CONTACT_1275], the patient should 
receive at least 4 U/kg in the study 
lower limb(s) every 12 to 14 weeks, 
with the total dose not to exceed the 
maximum specified for each 
treatment cycle .  For clarification 
5.4.1, Treatment Cycle 1 for De Novo Patients Specified that a total of 8 U/kg is to be injected either in the single study lower limb or divided between both study lower limbs only for diplegic patients. For clarification 
5.4.3, Treatment Cycles 2 Through 5 for All Patients (Rollover and de novo) Revised description of dose limitations  For clarification 
Table 3 Revised title to be more specific 
(Maximum Per-muscle, Per-limb, and Total Body Dose), added row for total maximum dose for both lower limbs, and added footnote to indicate that only 1 upper limb is to be injected. For clarification 
5.4.4, Treatment Regimen/Dosage Adjustment Added For purposes of dose 
calculation, the patient’s weight 
will be rounded to the nearest 
whole kilogram.    For clarification 
[IP_ADDRESS], Retreatment Criteria 
 Revised to “Patients should
 may be 
reinjected” if they meet the 
retreatment criteria. For clarification 
 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 90  
  Section(s) Revision Rationale 
5.4.5, Retreatment Visits Deleted sentence regarding dose 
(because that is specified in 
Section 5.4.3).  Revised the last sentence to “…determine if the patient will be eligible for retreatment and if the above-mentioned dosing regimens are clinically
 appropriate for the patient 
or dose reduction relative to the last 
injection received  is required. For clarification 
   
  
 
  
 
 
  
  
 
  
 
  
 
 
  
    
  
 
    
  
 
 
 
 
  
 
 
 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 91  
  Section(s) Revision Rationale 
 
  
   
  
  
 
 
 
 
 
  
 
  
  
 
 
 
 
 
 
 
 
 
8.7, Early 
Discontinuation of Patients Revised study week 42 to study week 48. Correction  
8.8, Withdrawal Criteria 
 Added that patients will be 
withdrawn from the study if they develop a medically significant hypersensitivity reaction to the study drug such as angioedema or anaphylaxis, or if a patient becomes pregnant during the study. For clarification 
 
  
 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 92  
  Section(s) Revision Rationale 
  
  
 
  
 
  
 
 
  
  
 
 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 93  
  12.6 Protocol Amendment 3 Summary 
Title:  BOTOX® Treatment in Pediatric Lower Limb Spasticity:  Open-label Study 
Protocol 191622-112, Amendment 3 
Date of Amendment:  January 2014 
Amendment Summary 
This summary includes changes made to Protocol 191622-112 Amendment 2 (e-signature 
[CONTACT_568] 28 November 2012).   
 
 
Following is a summary of content-oriented changes that were made to each section of the protocol, and a brief rationale for these change s.  Minor editorial a nd document formatting 
revisions have not been summarized. 
Section(s) Revision Rationale 
Title page Referred to the Study Contacts Page for 
emergency telephone numbers; updated page 2 Per new Allergan protocol 
template 
 
 
 
  
  
 
 
  
 
 
3.1 Changed “members” to “participants” and 
removed “or investigator” from the examples 
given of ad hoc SDRC participants Clarification 
 
  
  
 
Protocol Summary; 
4.4 Modified Exclusion Criterion 13a regarding seizure frequency for exclusion Clarification 
 Modified Exclusion Criterion 14 regarding vulnerable respi[INVESTIGATOR_687963] 29 to exclude 
patients with significant suicidality from 
treatment To avoid confounding the 
safety data 

 
 
Approval Date :  
 28-Jan-2014Allergan Confidential Protocol 191622-112 Amendment 3 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 94  
  Section(s) Revision Rationale 
Protocol Summary; 
 
  
  
 
 Added a sentence on use of anti-epi[INVESTIGATOR_687964]-
epi[INVESTIGATOR_687965] 
[IP_ADDRESS] Amended bullet (c) of the retreatment criteria To specify that patients who 
experience certain adverse 
events will not receive 
further study treatments 
5.4.5 Revised paragraph regarding retreatment for 
patients with adverse events of compromised 
respi[INVESTIGATOR_4806], aspi[INVESTIGATOR_1516], difficulty 
swallowing, or clinically significant excessive 
salivation  To specify that patients who 
experience these adverse 
events will not receive 
further study treatments 
6.4 Removed:  “Non-frost-free -20 °C freezer for 
storage of serum neutralizing antibody samples” Correction 
 Added bullet that Allergan will supply a 
kilogram-only weight scale for selected sites, 
and that the site will supply it only if it is not 
already supplied by [CONTACT_687983]’s 
weight is collected in 
kilograms only 
  
  
  
    
  
  
   
9.3 Updated serious adverse event la nguage Per new Allergan protocol 
template 
  
   
 
 
  
    
 
 
  
 
 
 
   
 

 
 
Approval Date :  
 28-Jan-2014ALLERGAN  
 
 
 
 
    
 
         
                
                         
                         
                  
                         
                         
                         
                         
                         
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
 Protocol 191622-112 Amd 3
